This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
137
1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
Unnamed facility
Deerfield Beach, Florida, United States
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the study eye, defined as the worse eye at Baseline. The mean diurnal IOP is the average of all the IOP measurements in the study eye taken at 8 AM, 10 AM and 4 PM at Baseline and at Week 12. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.